about
Reporting bias in medical research - a narrative reviewDo the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?Can analyses of electronic patient records be independently and externally validated? The effect of statins on the mortality of patients with ischaemic heart disease: a cohort study with nested case-control analysisAutomatic filtering and substantiation of drug safety signalsPostmarket drug surveillance without trial costs: discovery of adverse drug reactions through large-scale analysis of web search queriesStatin intolerance - a question of definition.Signal detection and monitoring based on longitudinal healthcare dataGrading quality of evidence and strength of recommendations: a perspective.Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients.Statins and osteoporosis: new role for old drugs.Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis.Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophages.Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.Effect of the statin atorvastatin on intracellular signalling by the prostacyclin receptor in vitro and in vivo.New lipid-modifying therapies.Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.Suboptimal choices and dosing of statins at start of therapyDetection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media.Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.Synergizing Engineering and Biology to Treat and Model Skeletal Muscle Injury and Disease.Quantification of cerivastatin toxicity supports organismal performance assays as an effective tool during pharmaceutical safety assessment.Observational research--opportunities and limitations.Pharmacogenomics in clinical practice and drug development.Surrogate end points: how well do they represent patient-relevant end points?Statins therapy: a review on conventional and novel formulation approaches.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis.A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.Systems pharmacology modeling: an approach to improving drug safety.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Current drug treatment of hyperlipidemia in older adults.Drug-drug interactions that interfere with statin metabolism.Handling Temporality of Clinical Events for Drug Safety Surveillance.Human biology-based drug safety evaluation: scientific rationale, current status and future challenges.Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells.
P2860
Q21203744-07B213CA-424A-4C1D-A836-420A1EEB3322Q24804153-AA57EAD0-A331-4C0C-876A-9C06A535CF0CQ28385268-6FA94500-798C-4C35-B524-0AAD20E1A596Q28482131-EAA23552-A4E8-4308-9126-AE0BA7EB084CQ28677138-D76B8164-EFA7-41AA-A369-328B983FB539Q30245218-F5B4E4E7-F827-4F92-986F-D6B024436F3BQ30706851-BC060C11-3147-40EB-9647-90B8AF2FEFBFQ33503216-0ABD457D-61A7-4C7E-8DA5-C078AE0A9FF9Q33692765-F834FBA7-F955-4AF3-990E-354CE9E52873Q34563901-1E9DD3AA-F165-426E-A297-97D12CDFC4B4Q34636525-BF40D2AD-82D7-48D3-AE66-5A46883A5A7CQ34680866-0B57DBAC-6CA6-47DB-B012-1A563DDF465EQ34989168-0B0E36E3-8FEE-421F-BD55-B5749D19BBACQ35009456-B806CCFF-F623-4B75-9E21-DE7505E7BBFAQ35035100-C8BCBD0D-9E5B-4039-AC64-A0A37362C3EBQ35047687-52AA88E7-59DF-4F5A-8CF2-2D7961DE9E99Q35073322-2CDCA99E-82D9-4F18-9484-69FAE80E682CQ35640331-72559298-E447-43D1-B33D-9213760EDF00Q35827103-2FCC635D-36C0-4923-81F2-3B06E6FCD1C5Q36320218-87F700D7-71B3-498F-84D9-FB561D622D7DQ36332525-4EB95A8C-D32A-4EE6-A4B5-462CE404CF4AQ36874154-AF69515C-A5B6-4293-A0D6-FAB719D5D87BQ36907503-76BE63C9-11BE-458A-879E-1FDD4F0DDAD0Q37282191-C4AEF087-5FDC-407A-B74B-7B90C0E9D21CQ37284234-94621595-0437-48D8-9EDC-5E18C11D98AEQ37755085-F1D90B6E-2012-4E4E-BE93-D9B0B8EE1185Q37896125-E4DEF822-1A40-4A20-A3A3-E88D020D7CE2Q37955160-082B5489-B9A4-4BC9-B24B-7E271790EE31Q38075078-8ACFB863-C0B7-494B-8259-B1FC6480951DQ38101731-E4896133-EE49-4D62-91EC-69CE6A8748CBQ38113494-C96CF545-D907-4082-B708-15C0F84D8E36Q38153621-46CA7146-ADB3-4493-8C82-7945628EE0ACQ38325814-E1E09BAB-B932-4B77-9173-7803F44EC600Q38338437-0E6769F6-B779-4ED2-8AFA-BDD1C6C7AFC3Q38522299-A7214C27-F317-40AD-BF34-95682FB31603Q38614242-4F960319-29A0-4F9D-8F4B-B5AAB6120537Q38763000-6F808AE0-B8E6-4B45-9814-6962CF3BA93AQ38851957-FBA08235-A5BB-4864-9448-5E03ADE01811Q38933872-AF901DD9-1127-4687-A491-4055CA5C9874Q38968601-2F354623-A063-4E81-9C90-71F64DEC0D9A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականին հրատարակուած գիտական յօդուած
@hyw
2001 թվականին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Withdrawal of cerivastatin from the world market
@ast
Withdrawal of cerivastatin from the world market
@en
Withdrawal of cerivastatin from the world market
@nl
type
label
Withdrawal of cerivastatin from the world market
@ast
Withdrawal of cerivastatin from the world market
@en
Withdrawal of cerivastatin from the world market
@nl
prefLabel
Withdrawal of cerivastatin from the world market
@ast
Withdrawal of cerivastatin from the world market
@en
Withdrawal of cerivastatin from the world market
@nl
P2860
P3181
P356
P1476
Withdrawal of cerivastatin from the world market
@en
P2093
Curt D Furberg
P2860
P2888
P304
P3181
P356
10.1186/CVM-2-5-205
P50
P577
2001-01-01T00:00:00Z
P5875
P6179
1015979413